Biocon, an innovation-led global biopharmaceutical company, has announced the successful completion of a Qualified Institutions Placement (QIP), raising INR 4,500 crore through the issuance of 13,63,63,635 equity shares of face value 5 each to eligible qualified institutional buyers at the issue price of INR 330 per equity share (including a premium of INR 325 per equity share).

The QIP, which opened on June 16, 2025, and closed on June 19, 2025, witnessed robust investor interest from a diverse group of domestic and international investors, underscoring strong confidence in Biocon's growth prospects, said the company in a statement.

Siddharth Mittal, CEO and Managing Director, Biocon Limited, said, “The strong response to our QIP reflects deep investor conviction in Biocon's differentiated strategy and consistent execution. This capital raise further strengthens our balance sheet, enabling us to invest in innovation, expand global access to lifesaving biopharmaceuticals, and advance our purpose of delivering affordable healthcare solutions that address pressing health inequities worldwide.”

The proceeds from the QIP will be utilised for the purchase of outstanding optionally convertible debentures issued by its subsidiary, Biocon Biologics, from Goldman Sachs India AIF Scheme - 1 and Goldman Sachs India Alternative Investment Trust AIF Scheme – 2. It will also be used for repayment, pre-payment or redemption, in full or in part, of certain outstanding financial instruments issued and/or borrowings availed by the company, and/or meeting other financial commitments and other general corporate purposes.

The company received shareholder approval for the fundraise via a postal ballot on June 4, 2025. The post-issue shareholding of the promoter and Promoter Group stands at 54.45 percent.